Research Reports
Stellar Innovation to drive the Biobetters Market
Published On :
The Biobetters Market is likely to mark stellar growth in the upcoming period. The current situation calls for conducive integrated healthcare models that do away with middlemen regarding offering various products and services. Drug manufacturers, hospital systems, PBMs (pharmacy benefit managers), wholesale distributors, hospital systems, medical insurers, and retail pharmacy outlets – are all into the integration of healthcare strategies. This would be how the healthcare vertical function in the upcoming period.
Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/21151
Increasing usage of therapeutically more effective drugs for the treatment of chronic diseases is expected to drive the growth of biobetters market. Higher efficacy and lower adverse effects are among the important factors that are expected to fuel the growth of the biobetters market over the forecast period. According to the latest research by the company, the global biobetters market is projected to account for a market value of around US$ 99,000.0 Mn by the end of 2029. The report also projects a significant growth potential for the biobetters market throughout the forecast period.
Company Profiles:
- F.Hoffmann-La Roche AG
- Merck & Co. Inc.
- Sanofi SA
- SERVIER
- Porton Biopharma Limited
- Eli Lily and Company
- Novo Nordisk A/S
- Biogen Inc.
- CSL Behring GmbH
- Teva Pharmaceutical Industries Ltd.
Request for Methodology@ https://www.persistencemarketresearch.com/methodology/21151
Better Therapeutic Outcome at Lower Costs
Lower cost of treating various chronic diseases with the usage of biobetters is one of the prominent factors contributing to the substantial growth of the biobetters market. Biobetters are more effective and longer-acting medicines as compared to biosimilars, which are their reference biologic products. Although biosimilars are 20 to 30% cheaper as compared to biobetters, superior efficacy and lesser dosage frequency makes biobetters a preferred treatment option.
Moreover, the treatment cost of each cycle using biobetters is relatively lower than that of biologics. For example, Neulasta, a biobetter of Neupogen, costs around US$ 3,400 – 4,000 for each treatment cycle, whereas Neupogen cost around US$ 6,000 at the inception. Although the cost of Neulasta increased considerably, it made only a little difference due to its increased patient compliance and efficacy. However, the market share of Neupogen and its biosimilars remains significantly low, when compared to Neulasta. The superiority of biobetters in terms of pricing, dosage, efficacy, etc. makes them among the most preferred treatment options among patients as well as healthcare professionals.
Various pharmaceutical and biopharmaceutical companies are seeking approval for their respective biobetters for the treatment various diseases. For example, on May 7, 2019, Roche received approval for its Kadcyla drug for the adjuvant treatment of HER2-positive early breast cancer in patients who are affected by residual invasive disease after undergoing neoadjuvant taxane-trastuzumab-based treatment. Kadcyla was earlier approved for the treatment of HER2-positive metastatic breast cancer. In March 2017, Roche received FDA approval for its drug named Ocrevus (ocrelizumab) for the treatment of the relapsing form of multiple sclerosis.
Access Full Report@ https://www.persistencemarketresearch.com/checkout/21151
Pharma and Biopharma Companies Investing in R&D
In terms of revenue, the insulin biobetters segment by drug class in the biobetters market is expected to be a prominent segment over the forecast period. By indication, the biobetters market is expected to be dominated by diabetes over the forecast period due to the higher prevalence of the disease. By route of administration, the subcutaneous segment of the biobetters market is expected to generate significant revenue during the forecast period due to superior drug delivery as compared to intravenous. By distribution channel, the biobetters market is expected to be dominated by the retail pharmacies segment due to higher patient footfall.
North America is expected to be a prominent biobetters market through 2029. Biobetters are approved through the biologics approval pathway as new molecules and hence, they have 10 to 12 years of marketing exclusivity in regions such as North America and Europe, which allows pharmaceutical and biopharmaceutical companies to invest in R&D as it provides assurance to the manufacturers. The manufacturers of originator biologics tend to develop biobetters of their own product, which allows them to maintain/increase their market share due to the superior qualities of biobetters even after the patent expiry of originator biologics. For example, Amgen Inc., a manufacturer of Neupogen, launched Aranesp, a drug used for the treatment of anaemia in patients suffering from chronic kidney diseases as well as chemotherapy/radiation-induced myelosuppression in cancer patients.
About Us: Persistence Market Research
Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Japan Office: 1-2-1 Kinshi Arca Central Building
14/F Tokyo, 130-0013, Japan
Call 1-888-863-3700
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com
Uma Rajagopal has been managing the posting of content for multiple platforms since 2021, including Global Banking & Finance Review, Asset Digest, Biz Dispatch, Blockchain Tribune, Business Express, Brands Journal, Companies Digest, Economy Standard, Entrepreneur Tribune, Finance Digest, Fintech Herald, Global Islamic Finance Magazine, International Releases, Online World News, Luxury Adviser, Palmbay Herald, Startup Observer, Technology Dispatch, Trading Herald, and Wealth Tribune. Her role ensures that content is published accurately and efficiently across these diverse publications.
-
-
BUSINESS3 days ago
UK pay growth weakest since February 2021, REC survey show
-
-
-
NEWS3 days ago
Japan leads Asia stock rally, dollar firms after blowout US payrolls
-
-
-
NEWS3 days ago
Adani Group in talks to buy Heidelberg’s Indian cement operations, paper says
-
-
-
INVESTING3 days ago
Manchester-based mobile network sees unprecedented growth and attracts major investment.
-